March 28, 2018
1 min read

Loteprednol reduces IOP, medications after canaloplasty

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

IOP remained reduced in patients given loteprednol etabonate suspension 0.5% after canaloplasty, with or without cataract surgery, according to a study.

The retrospective chart review was conducted at Dean McGee Eye Institute, University of Oklahoma. Data were collected for 204 patients who underwent canaloplasty with or without cataract surgery, with 58 undergoing surgery in both eyes on separate days. Nearly 92% of eyes were diagnosed with primary open-angle glaucoma with or without nuclear sclerotic cataract at the time of surgery.

The most frequent dosing regimens of loteprednol etabonate suspension 0.5% were four times daily on day 1 in 241 of 261 eyes, three times daily at week 1 in 133 of 253 eyes, and once daily at 1 month in 78 of 119 eyes.

No IOP-lowering medication was needed in 78.8% of eyes with pressure of 21 mm Hg or less followed up at 6 months; these were considered complete successes. Qualified success, which was the need for two or fewer IOP medications, was achieved in 90.6% of these eyes.

Hyphema was the most frequently observed early postoperative complication observed in 48.7% of eyes at day 1. By month 1, hyphema cases decreased to just 0.4% of eyes. Most complications occurred in the early postoperative period, according to the study.

“Significant IOP reduction was achieved rapidly and sustained over a period of years with minimal need for adjunct medication use,” the study authors said. – by Robert Linnehan

Disclosures: The researchers report no relevant financial disclosures.